Catalent, Inc. (CTLT)

55,92 +0,12 (+0,22%) Börsenschluss: 04:00PM EDT

Catalent, Inc.

14 Schoolhouse Road
Somerset, NJ 08873
United States
732 537 6200
https://www.catalent.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 18.000

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Alessandro Maselli	President, CEO & Director	1,08M	N/A	1972
Dr. Aristippos Gennadios Ph.D.	Group President of Pharma & Consumer Health Segment	799,26k	N/A	1966
Mr. Ricky Hopson	President, Division Head for BioProduct Delivery & Chief of Staff	622,12k	N/A	1977
Mr. John J. Greisch M.B.A.	Executive Chairman of the Board	125k	N/A	1955
Mr. Matti M. Masanovich	Senior VP & CFO	N/A	N/A	1972
Mr. Michael J. Hatzfeld Jr.	VP & Chief Accounting Officer	N/A	N/A	1973
Mr. Charles Lickfold	Senior VP & Chief Information Officer	N/A	N/A	1974
Mr. Paul Surdez	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Joseph A. Ferraro J.D.	Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary	N/A	N/A	1978
Mr. Michael J. Grippo	Senior Vice President of Strategy & Corporate Development	N/A	N/A	1969

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Corporate Governance

Catalent, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 10. Die grundlegenden Scores sind Audit: 10, Vorstand: 8, Shareholderrechte: 7, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.